Navigation Links
Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
Date:8/17/2011

WALTHAM, Mass., Aug. 17, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."  This allowance follows the recent US issuance which was granted in June adding to the extensive patent estate for the Company's lead product, entinostat.

The patent covers the novel polymorph form B of the oral histone deacetylase inhibitor, entinostat, which is the specific polymorph being developed by Syndax for combination therapy with aromatase inhibitors for metastatic breast cancer and epidermal growth factor receptor tyrosine kinase inhibitors  for advanced non-small cell lung cancer.

"This European allowance combined with the recent US issuance provides a strong patent position for entinostat, our lead product candidate, as we move forward into phase 3 testing for women with metastatic breast cancer," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "We look forward to presenting the results from our randomized phase 2 placebo-controlled study in metastatic breast cancer at the ASCO 2011 Breast Cancer Symposium in September.  We believe entinostat may help address the significant need to improve outcomes for the thousands of women in the United States living with metastatic breast cancer by extending the benefit of hormone therapy and delaying initiation of chemotherapy."  

About Entinostat

Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Syndax Pharmaceuticals to Present at BIO Investor Forum
2. Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
6. European Medicines Agency Accepts Vanda Pharmaceuticals Inc.s Marketing Authorization Application For Oral Iloperidone Tablets
7. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
8. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
9. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
10. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
11. Amylin Pharmaceuticals to Present Promising New Data on the Companys Diabetes Programs at ADA 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Huge event with 36,000+ global professionals is ... analysis and forecasting   CPhI Worldwide , ... most successful show to date with pre-audit figures estimating ... year in Paris , the show ... countries representing every step of the pharmaceutical supply chain ...
(Date:10/31/2014)... Ill. (PRWEB) October 31, 2014 Jeffrey ... Department of Historical Studies within the College of Arts ... SIUE to record the history of alcohol-based fuels in ... and many others have been working to build Illinois’ ... important but overlooked aspect of the state's agricultural and ...
(Date:10/31/2014)... 31, 2014 ENVIRON , ... announced today that Dr. Harvey Clewell III has ... will work closely with senior professionals in ENVIRON’s ... to serve at The Hamner Institutes for Health ... Carolina, where he is Director, Center for Human ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... ... Capital,s client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private ... as Neuren,s exclusive placement agent and advisor. , ... New York (PRWEB) November 23, 2009 -- The independent ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it has ... common stock will be,suspended as of November 30, 2009 and a ... will remove deCODE,s common stock,from listing on Nasdaq, unless the company ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
Cached Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... developed a small-molecule inhibitor of a protein that plays ... they show that the inhibitor can halt the growth ... culture. The findings are reported in companion papers reported ... Jan-Michael Peters of the Research Institute of Molecular Pathology ...
... developed at the University of Toronto is revealing biochemical ... could one day pave the way for pharmaceutical applications. ... issue of Molecular Cell describes how U of T ... test for proteins that play an important role in ...
... popular game fish mistaken by scientists for a dog ... reefs of the Abrolhos region of the South Atlantic ... discovery of Lutjanus alexandrei, a new snapper species that ... of Conservation International (CI) and Kenyon Lindeman of Environmental ...
Cached Biology News:New protein inhibitor impedes growth of cancerous cells 2Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... Rabbit polyclonal to Rad51 ( Abpromise ... Antigen: Synthetic peptide: ... N terminal amino acids 15-29 of ... Gene ID: 5888 ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
Biology Products: